(UroToday.com) The treatment landscape in advanced prostate cancer has rapidly evolved. In the context of metastatic castration-resistant prostate cancer (mCRPC), docetaxel was the first agent to demonstrate a survival benefit when combined with conventional androgen deprivation therapy (ADT). Following this, a number of other treatment approaches have been assessed and are now clinically used including androgen receptor targeting agents, immunotherapy approaches, and targeted therapy. In 2010, Sipuleucel-T immunotherapy was the first FDA-approved agent after docetaxel for mCRPC.